Core Viewpoint - The company has signed an exclusive strategic cooperation agreement with Inmunotek to introduce the Oraltek® series of desensitization drugs to the Chinese market, addressing the significant challenges in the allergy treatment industry and meeting the needs of allergy patients [1] Group 1: Strategic Cooperation - The company will exclusively introduce Inmunotek's Oraltek® series desensitization drugs in China, focusing on domestic sales and registration [1] - This partnership aims to enhance the company's new business in the domestic desensitization drug sector, facilitating the development of the allergy treatment industry [1] Group 2: Clinical Trials and Regulatory Approvals - The company's wholly-owned subsidiary, Shanghai Haobio, has successfully completed the first batch of subject enrollment for the Phase III clinical trial of the desensitization drug MM09 sublingual spray [1] - Three products targeting cat hair, dog hair, and house dust mites have received the "urgent clinical need import permit for Hong Kong and Macau drugs" under the Guangdong Provincial Drug Administration's policy [1]

Core Viewpoint - The company has successfully completed the initial enrollment and administration of the desensitization drug MM09 sublingual spray in a Phase III clinical trial, in collaboration with Inmunotek [1] Group 1: Company Developments - The company received notification from its wholly-owned subsidiary, Shanghai Haooubo Biopharmaceutical Co., Ltd., regarding the successful completion of the first batch of subject enrollment for the MM09 sublingual spray [1] - The company is positioned as a leading entity in the field of allergy diagnosis and is expanding its business into allergen desensitization treatment, filling a domestic gap in this area [1] Group 2: Industry Impact - The development of the MM09 sublingual spray is expected to promote the company's "diagnosis and treatment integration," enhancing the synergy between allergy diagnosis and desensitization treatment [1] - This initiative aims to provide a more convenient and efficient desensitization treatment solution for domestic allergy patients [1]

Core Viewpoint - The company is a leading player in the allergy and autoimmune testing market in China, with a strong focus on technology and innovation, positioning itself for significant growth in both domestic and international markets [1][2]. Group 1: Company Overview - The company specializes in allergy and autoimmune testing, holding over 30% market share in China and covering more than 1,700 medical institutions, including 700 tertiary hospitals [1]. - It is one of the few companies globally that has mastered fully automated quantitative testing technology in the autoimmune testing field, with a product range that includes 75 types of IgE allergens and 81 types of food-specific IgG tests [1]. - The company invests over 10% of its revenue in R&D annually, with a projected R&D expense ratio of 11.5% in 2024, and has secured 62 patents and 230 product registration certificates as of mid-2025 [1]. Group 2: Market Potential - The global allergy diagnostics market is projected to reach 38.94 billion yuan in 2024 and exceed 71.85 billion yuan by 2030, while the autoimmune disease diagnostics market is expected to grow from approximately 14.2 billion USD in 2022 to 17.9 billion USD by 2028 [2]. - The company has received five FDA certifications and full CE certifications for its products, allowing entry into high-end markets such as the UK, France, and Germany [2]. - The company is focusing on emerging markets in the Middle East, Southeast Asia, and Latin America, with a forecasted 33.38% growth in overseas revenue in 2024, reaching 17.76 million yuan [2]. Group 3: Financial Projections - Revenue forecasts for the company are 451 million yuan, 507 million yuan, and 573 million yuan for 2025-2027, with year-on-year growth rates of 12.09%, 12.42%, and 13.02% respectively [2]. - The projected net profit attributable to the parent company is 48 million yuan, 74 million yuan, and 89 million yuan for the same period, with growth rates of 29.37%, 55.32%, and 20.01% respectively [2]. Group 4: Valuation - The company is compared with similar firms in the industry, with an expected average PE of 22.43 times in 2025 [3]. - The company's competitive advantages, driven by its core technology and the strong global sales network of its parent company, are expected to facilitate its market leadership and accelerate both domestic and international expansion [3].